Nantahala Capital Management, LLC Adc Therapeutics Sa Transaction History

Nantahala Capital Management, LLC

  • $1.99 Billion
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
SELL
$0.72 - $2.37 $419,643 - $1.38 Million
-582,838 Reduced 69.39%
257,162 $231,000
Q1 2023

May 15, 2023
BUY
$1.92 - $5.45 $1.15 Million - $3.25 Million
596,710 Added 245.27%
840,000 $1.64 Million
Q4 2022

Feb 14, 2023
BUY
$2.87 - $5.24 $698,242 - $1.27 Million
243,290 New
243,290 $934,000

Others Institutions Holding ADCT

# of Institutions
85
Shares Held
55.3M
Call Options Held
24.1K
Put Options Held
44.7K
View Full List

About ADC Therapeutics SA

ADCT Quotes by TradingView
  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $125M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Nantahala Capital Management, LLC Portfolio

Follow Nantahala Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nantahala Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email